EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Asciminib

摘要

Initial indication: a. Accelerated approval in adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase (CP) that has previously been treated with 2 or more tyrosine kinase inhibitors (TKIs) b. Approval in adult patients with Philadelphia chromosome-positive CML in CP harboring T315I mutations.